Navigation Links
U.S. Pharmaceutical Budget and Staffing: Powerful New Metrics-Based Study
Date:5/7/2008

CHAPEL HILL, N.C., May 7 /PRNewswire/ -- In today's marketplace, pharmaceutical and biotechnology companies are experiencing intense pricing, political, regulatory and market pressures. These forces are creating stress on the industry's fundamental business model. Consequently, pharmaceutical and biotechnology companies must evaluate the optimal levels of human and capital investment in the commercial enterprise to ensure health and competitiveness.

Due to increasing prices and shrinking margin pressures, few, if any, companies can ignore how many people they staff to critical functions. Best Practices, LLC's benchmarking study analyzes resource allocation specific to key business functions in the pharmaceutical and biotechnology industries and can further assist business unit managers in assessing their level of staffing investment and resources channeled into different business functions.

A sample of analyzed functions in the report is:

-- Marketing -- this is further segmented, analyzed, and benchmarked on

the basis of product

-- State Government Affairs -- benchmarking data segmented by sales

revenues provide greater insight and highlights trends

-- Finance -- segmented and benchmarked by sales revenues to provide

greater insight and trends

If you have to defend or validate budget and staffing resource decisions, the Best Practices Pharmaceutical Budget and Staffing Benchmark Guide will prove invaluable. The rich metrics contained in this comprehensive report emanate from survey responses from staffing executives at such elite pharmaceutical and biotech companies as Abbott Labs, AstraZeneca, Bristol-Myers Squibb, J&J, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, Roche and Sanofi-Aventis.

To download a free excerpt of U.S. Pharmaceutical Budget and Staffing Excellence visit http://www3.best-in-class.com/rr
'/>"/>

SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014 The report expects global ... by 2019. It also provides a carefully analyzed data ... challenges for the market. , Full Copy of Report ... the global market for cell expansion will keep witnessing ... expects this growth to be driven by rapid technological ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, ... focused on gynecologic disease, announced today that investors ... , Birchview Fund LLC and several Vermillion directors ... unregistered shares of Vermillion,s common stock and warrants ... in a private placement.  Under ...
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Sept. 16 Genoptix, Inc.,(Nasdaq: GXDX ), a ... the UBS Global Life Sciences Conference,scheduled to take place ... September 22,- 25, 2008., Douglas Schuling, Senior Vice ... on Monday, September 22, beginning at,approximately 3:30 pm EDT. ...
... answer to ensuring a safe supply of drinking water ... or where water contamination is rife. Writing in the ... India explain how carbon nanotubes could replace conventional materials ... access to safe drinking water will continue to grow ...
... Symmetry Medical Inc.,(NYSE: SMA ), a leading ... and other medical markets, announced today that,Brian S. Moore, ... the UBS Global Life Sciences Conference at The Grand ... 25, 2008 at 11:30 a.m. ET., A live ...
Cached Biology Technology:Genoptix Announces Participation at the UBS Global Life Sciences Conference 2Water purification down the nanotubes 2Symmetry Medical to Present at UBS Global Life Sciences Conference 2
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research ... announced the addition of the "Samsung Galaxy ... Analysis" report to their offering. ... on a totally different sensing technology than the ... a fingerprint sensor in its product. ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is ... Facial recognition system measures the overall facial feature ... mouth, and the distance between eyes. Facial recognition ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... ON (Dec. 22, 2011) - Drugs used to overcome ... study led by Gerry Wright, scientific director of the ... McMaster University. "Our study found that certain proteins, ... to proteins important in cancer," says Wright about the ...
... 2011(BRONX, NY) Researchers at Albert Einstein College of Medicine ... mechanism by which cells control the survival of messenger RNA ... pertain to mRNAs that help regulate cell division and could ... research is described in today,s online edition of the journal ...
... tragic losses to life, property, and the environment. But ... from done. Without vegetation, bare, burnt soil lies vulnerable ... regeneration. Now Assaf Inbar, a graduate student ... together with his supervisors Prof. Marcelo Sternberg of the ...
Cached Biology News:Built-in 'self-destruct timer' causes ultimate death of messenger RNA in cells 2Built-in 'self-destruct timer' causes ultimate death of messenger RNA in cells 3Reclaiming the land after a forest fire 2
... use spatulas have been designed to save ... for those interested in eliminating the recycling ... spatula is individually packaged, RNase/DNase free, non-pyrogenic ... a new product number, created to easily ...
... have been designed to save time and ... interested in eliminating the recycling and resterilizing ... individually packaged, RNase/DNase free, non-pyrogenic and antistatic. ... product number, created to easily match Cornings ...
... Phosphatase Detection Kit (Catalog number SCR004) is ... phenotypic assessment of ES cell differentiation by ... separately from CHEMICON are the monoclonal antibodies ... Number MAB4354), which permit the detection of ...
... The SYS203 is a complete, ... measurement in small samples, as is ... system is designed around Instechs miniature ... of an inch in diameter (3.2 ...
Biology Products: